John Woolburn

John Woolburn asked for more information on the 2,000 potential hypothalamic obesity (HO) patients identified, specifically whether Rhythm Pharmaceuticals has been able to determine who among them might be good candidates for Imcivree.

Answer

Jennifer Lee, EVP, Head of North America, Rhythm Pharmaceuticals, explained that the 2,000 patients were identified through field organization discussions with physicians, who either formally diagnosed HO patients or identified those meeting criteria for further evaluation. She noted that this process is ongoing and that there is significant physician interest in diagnosing these patients, leading to an addressable opportunity for quicker diagnosis and potential Imcivree treatment.

John Woolburn asked for more information on the 2,000 potential HO patients identified, specifically whether Rhythm Pharmaceuticals has been able to determine their candidacy for treatment.

Answer

Jennifer Lee, EVP, Head of North America, clarified that the 2,000 patients were identified through field organization discussions with physicians who either formally diagnosed them or identified them as meeting criteria for further evaluation. She noted that this process is ongoing, with significant physician interest in achieving a specific diagnosis.